News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zogenix, Inc. and Desitin Pharmaceuticals GmbH Announce Marketing Approval for SUMAVEL(R) DosePro(TM) in Germany and the United Kingdom


1/6/2011 9:52:21 AM

SAN DIEGO and HAMBURG, Germany, Jan. 6, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) and Desitin Pharmaceuticals GmbH ("Desitin") today announced that the Federal Institute for Drugs and Medical Devices of Germany (BrArM), and the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA) have approved the Marketing Authorization Application (MAA) for SUMAVEL® DosePro™ (sumatriptan injection) Needle-free Delivery System for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache.

Read at GlobeNewswire


comments powered by Disqus
   
Migraine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES